Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
- Status
- TERMINATED
- Phase
- PHASE1
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
- Status
- COMPLETED
- Phase
- PHASE1
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
- Status
- TERMINATED
- Phase
- PHASE2
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE4
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
- Status
- COMPLETED
- Phase
- PHASE2